Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 3:29am EST - Canadian Markets open in 6 hours and 1 minute.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
Novogen Limited (NVGN)
On Feb 9:
2.34 USD
0.00 (0.00%)
MORE ON NVGN
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
Novogen Limited
(NGM:NVGN) Delayed quote data
Last Trade:
2.34 USD
Trade Time:
Feb 9
Change:
0.00 (0.00%)
Prev Close:
2.34
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
N/A
Day's Range:
N/A - N/A
52wk Range:
1.23 - 7.00
Volume:
0
Avg Vol
(3m)
:
10,730.2
Market Cap:
47.79M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.81
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add NVGN to Portfolio
Download Data
HEADLINES
Marshall Edwards, Inc.'s Action Intended to Regain Compliance With Nasdaq Share Price Rule, Benefit Shareholders
Marketwire
(Tue 3:30pm)
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
Marketwire
(Mon, Feb 8)
Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
Marketwire
(Thu, Jan 21)
Culp, Novogen: Biggest Price Gainers (CFI, NVGN)
at The Wall Street Journal Online
(Mon, Dec 7)
Marshall Edwards, Inc. Appoints Acting CEO
Marketwire
(Tue, Dec 1)
Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
Marketwire
(Tue, Sep 29)
Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Marketwire
(Tue, Sep 22)
NOVOGEN LTD Financials
EDGAR Online Financials
(Tue, Aug 18)
Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Marketwire
(Wed, Aug 5)
Novogen Director Retires
Marketwire
(Thu, Jul 30)
More Headlines for NVGN...
ANALYST
EPS Est (next year)
(Dec-69)
:
N/A
EPS Est (in 2 years)
(Dec-69)
:
N/A
Avg Rec (current)*:
1.0
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The companys consumer healthcare products comprise Promensil, a range of natural products ...
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices